Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.

European journal of clinical pharmacology - 1 Dec 2009

Arbouw Maurits E L, Movig Kris L L, Egberts Toine C G, Poels Petra J E, van Vugt Jeroen P P, Wessels Judith A M, van der Straaten R J H M, Neef Cees, Guchelaar Henk-Jan

Abstract excerpt

OBJECTIVE: To identify determinants for the discontinuation of non-ergoline dopamine agonist (DA) treatment in patients with Parkinson’s disease (PD) and to identify genetic determinants in genes encoding dopamine receptor (DR)D2 and DRD3 in a exploratory analysis. METHODS: Patients included were first-time users of the non-ergoline DA ropinirole or pramipexole who had been diagnosed with PD before 2005....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzothiazoles
Share to Contraindications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Agonists

Share to Indoles

Share to Parkinson Disease

Share to Pharmacogenetics

Share to Receptors, Dopamine D2

Share to Receptors, Dopamine D3

Source

Open in PubMed Open full text

Identifiers

PMID: 19669131
DOI: 10.1007/s00228-009-0708-6
PMCID: PMC2778789

Genes

DRD2
DRD3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.PMID 19669131Read ↗

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocolSemantic proximity Read ↗

The role of pharmacogenomics in the discontinuation of psychotropic medication: a scoping review protocolSemantic proximity Read ↗

Common and rare variant contributions to discontinuation of stimulant treatment in ADHD.Semantic proximity Read ↗

Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort StudySemantic proximity Read ↗

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.Semantic proximity Read ↗

Association of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder.Semantic proximity Read ↗

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Semantic proximity Read ↗

<scp>l</scp>-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphismSemantic proximity Read ↗

Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents.Semantic proximity Read ↗

Trials evaluating drug discontinuation: a scoping review sub-analysis focusing on outcomes and research questionsSemantic proximity Read ↗

Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment.Semantic proximity Read ↗

Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic lociSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.